← Back to headlines
Vir Biotechnology Secures $1.7B Deal with Astellas for Prostate Cancer Asset
Vir Biotechnology's stock surged following the announcement of a deal worth up to $1.7 billion with Astellas to advance a prostate cancer asset.
23 Feb, 22:39 — 23 Feb, 22:39
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
FDA Flags Major Philippine Retailers for Unregistered Products
just now
Chocolate kept in anti-theft boxes as retailers warn it's being stolen to order
13m ago
SI-BONE Forecasts 14%-16% Revenue Growth for 2026 Driven by New Products and Partnership
14m ago
JPMorgan's Dimon Emphasizes Organic Growth and Technology's Transformative Impact
16m ago